This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Healthcare technology is advancing at a mind-bending pace. Companies must create unique and reliable products in order to stand out amongst the growing competition. billion by 2026 , so take the steps to create a successful medtech marketing strategy now as the industry is still growing.
The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. They drive competition and cost savings, helping to address the rising financial pressures faced by global healthcare systems.
healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes. Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026.
As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. They do not have biosimilar or generic competition available in the market.
Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.
Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. billion by 2026, according to research by the Business Research Company. billion in 2021 to $9.23 References.
GlobalData’s Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 report offers insights on application of blockchain in healthcare and other key sectors.
The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. exclusions exist for orphan drug designation and biosimilar competition ).
FDA approval in the fourth quarter, with Johnson & Johnson’s Varipulse system close behind, so competition will pick up. Abbott’s Volt should join the party in early 2026. Still, analysts and providers project that Farapulse, which has more than 70% of the global market today, will continue to dominate at least through 2025.
Confidence Amidst Funding Challenges The resilience and confidence observed amidst funding challenges within the biotech sector represent a testament to the industry’s steadfast commitment to innovation and transformative advancements in healthcare.
However, a delicate balance will need to be struck between the need for affordable and accessible medicinal products and the desire to foster innovation and competitiveness in the EU. Edward Turtle is a products lawyer, regulatory advisor and litigator with particular experience in the healthcare, technology and consumer product sectors.
If you’re someone that’s trying to get into medical sales, maybe it’s pharmaceutical, medical device, or any kind of healthcare sales, then you better be tuning in to this episode. They’re healthcare sales reps. If it’s 2026 and you’re reading this, this happened in 2023.
That way, they can continue to grow membership and thrive against the competition. In 2026, payers will need to send prior authorization decisions within 72 hours for urgent requests and seven business days for standard requests. These changes are designed to make care easier to access for enrollees.
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. That impacts launches most. Lastly, the growing economic crisis creates increasing challenge for medicines funding. appeared first on.
healthcare system with major implications for the Medicare Advantage and Medicare Part D programs. Maximum Fair Prices published: The first round of negotiated Maximum Fair Prices will be published in August 2024, scheduled to take effect in 2026. On August 16, 2022, President Biden signed the Inflation Reduction Act (IRA) into law.
Medical sales reps frequently struggle to explain intricate device features and benefits, especially when their audience consists of busy healthcare professionals with limited time and high expectations. In todays highly competitive market, immersive medical sales technology is no longer optionalits essential.
Price negotiations will be staggered over time, beginning with this initial list of ten Part D drugs that takes effect in 2026 (Part D is the prescription drug coverage component of Medicare, a federal health insurance program for people 65 and older which covers nearly 1 in 5 Americans). These ten drugs cost Medicare Part D nearly $46.8
2024 was a pivotal year for AI in healthcare. The rapid growth in investment and adoption of AI in healthcare in 2024 brings a new wave of legal and regulatory developments. As we kick off 2025, those deploying AI in healthcare must be cognizant of new compliance requirements under federal and state law.
For healthcare marketers, we share the importance of simplicity, clarity, and local outreach in connecting with tech-savvy boomers and aging Gen Xers, as well as the strategies needed to avoid ANOC (Annual Notice of Change) shock and reduce member churn. Retaining loyal members requires a smart, tailored approach to stay competitive."
Healthcare delivery has not been the hottest topic on the campaign trail this election season, despite sharp policy differences between the candidates and parties. These prior actions align with the Biden Administration’s policy of strict antitrust enforcement, particularly concerning healthcare. During the Sept.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content